STAT+: Neurocrine reports second late-stage trial success for congenital adrenal hyperplasia drug

Neurocrine Biosciences announced that its experimental drug for congenital adrenal hyperplasia succeeded in a late-stage trial of children and adolescents.
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks